Steven D. Wood - 18 Dec 2023 Form 4/A Insider Report for MEI Pharma, Inc. (MEIP)

Role
Director
Signature
/s/ Justin J. File, as attorney in fact
Issuer symbol
MEIP
Transactions as of
18 Dec 2023
Net transactions value
$0
Form type
4/A
Filing time
12 Jan 2024, 16:00:05 UTC
Date Of Original Report
20 Dec 2023
Previous filing
14 Nov 2023
Next filing
21 May 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MEIP Stock Option (Right to Buy) Award $0 +6,700 $0.000000 6,700 18 Dec 2023 Common Stock 6,700 $6.19 Direct F1
transaction MEIP Stock Option (Right to Buy) Award $0 +10,000 $0.000000 10,000 18 Dec 2023 Common Stock 10,000 $6.19 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option shall be vested and exercisable with respect to 12.5% of the shares on the date of grant and the remainder of the option will vest and become exercisable in equal monthly amounts of 12.5% of the shares subject to the option, beginning on the first day of each calendar month following the date of grant (January 1, 2024) and continuing through July 1, 2024 with full vesting on July 1, 2024, subject to continued service through the applicable vesting date.
F2 Such option shall vest and become exercisable in 36 equal monthly installments, with the first installment vesting on the one-month anniversary of the date of grant, subject to continued service through the applicable vesting date.

Remarks:

This amendment is to correct the exercise price reflected in the Form 4 as originally filed ($6.33) to $6.19, which was the purchase price on the grant date and is the exercise price of the options.